851776-32-4Relevant academic research and scientific papers
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice
Semple, Graeme,Skinner, Philip J.,Gharbaoui, Tawfik,Shin, Young-Jun,Jung, Jae-Kyu,Cherrier, Martin C.,Webb, Peter J.,Tamura, Susan Y.,Boatman, P. Douglas,Sage, Carleton R.,Schrader, Thomas O.,Chen, Ruoping,Colletti, Steven L.,Tata, James R.,Waters, M. Gerard,Cheng, Kang,Taggart, Andrew K.,Cai, Tian-Quan,Carballo-Jane, Ester,Behan, Dominic P.,Connolly, Daniel T.,Richman, Jeremy G.
experimental part, p. 5101 - 5108 (2009/08/07)
The discovery and profiling of 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro- cyclopentapyrazole (5a, MK-0354), a partial agonist of GPR109a, is described. Compound 5a retained the plasma free fatty acid lowering effects in mice associated with GPR109a agonism,
METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS
-
Page/Page column 43-44, (2010/10/20)
A method of treating atherosclerosis, dyslipidemia and related conditions is disclosed wherein a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof is administered to the patient in combination with a DP receptor antagonist. T
COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS
-
Page/Page column 76-77, (2010/11/30)
The invention provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist. In addition, the invention provides a
TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF
-
Page/Page column 61-62, (2010/02/11)
The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present in
